A common, non-invasive skin imaging technique can predict which melanoma patients face a higher risk of metastasis as accurately as current methods that require analyzing tumor samples after surgery.
A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between PFS and OS suggests that resistance remains a major hurdle. As with other ...
Dual art therapy, combining music and painting, significantly improved symptoms, cognitive function, and quality of life in ...
Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...
As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...
The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...
The Managed Healthcare Executive 2025 State of the Industry survey is a timely snapshot of how payers, providers and pharmacy ...
Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...
Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...
RZV offers substantial clinical and economic benefits but has low uptake among adults aged 50 and older compared to other vaccines. By 2020, only 10.8% of adults aged 50 and older had completed both ...
Early ctDNA clearance, combined with complete response on PET-CT, correlates with prolonged progression-free survival. ctDNA testing is minimally invasive and can be conducted repeatedly, offering a ...
In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback